Filtered By:
Condition: Thrombosis
Drug: Clopidogrel
This page shows you your search results in order of date. This is page number 18.
Order by Relevance | Date
Total 536 results found since Jan 2013.
Antithrombotic strategy and its relationship with outcomes in patients with atrial fibrillation and chronic coronary syndrome
This study aimed to explore antithrombotic strategy and its relationship with outcomes in patients with atrial fibrillation (AF) at high risk for stroke and chronic coronary syndrome (CCS) in real-world clinical practice. Patients with AF at high risk for stroke complicated with CCS from China Atrial Fibrillation Registry (CAFR) were enrolled. The patients were divided into non-antithrombotic (Non-AT) group, oral anticoagulants (OAC) group, antiplatelet therapy (APT) group (aspirin or clopidogrel), and dual antiplatelet therapy (DAPT) group (aspirin + clopidogrel) according to their antithrombotic strategies at baseli...
Source: Journal of Thrombosis and Thrombolysis - October 22, 2021 Category: Hematology Source Type: research
Utility of a pharmacogenetic-driven algorithm in guiding dual antiplatelet therapy for patients undergoing coronary drug-eluting stent implantation in China
ConclusionTailored DAPT based on the PRiS could assist in improving the prognosis of patients undergoing DES implantation. Further randomized controlled trials are required to provide more evidence for PRiS-guided DAPT.
Source: European Journal of Clinical Pharmacology - October 12, 2021 Category: Drugs & Pharmacology Source Type: research
New Phase 3 Data Suggest Positive Effect and Show Similar Safety with XARELTO ® (rivaroxaban) Compared to Aspirin in Pediatric Fontan Procedure Patients at Risk for Blood Clots and Blood Clot-Related Events
RARITAN, NJ, September 27, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new data from the Phase 3 UNIVERSE study showing treatment with XARELTO® (rivaroxaban) in an oral suspension formulation, compared to treatment with aspirin, was associated with numerically fewer blood clots and clinical events strongly associated with blood clots in pediatric patients (aged 2-8 years) who have undergone the Fontan procedure. [1] These findings, which were published this month in the Journal of the American Heart Association and included in a recent New Drug Application submitted to the U.S. F...
Source: Johnson and Johnson - September 27, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO ® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
RARITAN, N.J., August 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. The approval is based on data from the Phase 3 VOYAGER PAD study. With this approval, XARELTO® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) events in p...
Source: Johnson and Johnson - August 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
E-004 Focal intracranial vasculopathy as a manifestation of COVID-19-associated acute ischemic stroke
ConclusionTo our knowledge, our case is the first to illustrate the potential for COVID-19 infection to present as a focal intracranial vasculopathy in an otherwise healthy young-patient, resulting in acute ischemic stroke without an underlying hypercoagulable state. Rescue intracranial stenting was necessary to maintain vessel patency and restore intracranial flow.Disclosures A. Mahapatra: None. A. Witek: None. G. Toth: None.
Source: Journal of NeuroInterventional Surgery - July 26, 2021 Category: Neurosurgery Authors: Mahapatra, A., Witek, A., Toth, G. Tags: Electronic poster abstracts Source Type: research
Effects of aging on clinical outcomes in patients receiving genotype ‐guided P2Y12 inhibitor selection after percutaneous coronary intervention
ConclusionThis study suggests important clinical benefits ofCYP2C19 genotype-guided antiplatelet therapy after PCI in both younger and older patients.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - July 21, 2021 Category: Drugs & Pharmacology Authors: Brian Wood,
Craig R. Lee,
Ian R. Mulrenin,
Megan N. Gower,
Joseph S. Rossi,
Karen E. Weck,
George A. Stouffer Tags: TI on Advances in Cardiovascular Pharmacotherapy Source Type: research
Effects of Aging on Clinical Outcomes in Patients Receiving Genotype ‐Guided P2Y12 Inhibitor Selection after Percutaneous Coronary Intervention
ConclusionThis study suggests important clinical benefits ofCYP2C19 genotype-guided antiplatelet therapy after PCI in both younger and older patients.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - July 10, 2021 Category: Drugs & Pharmacology Authors: Brian Wood,
Craig R. Lee,
Ian R. Mulrenin,
Megan N. Gower,
Joseph S. Rossi,
Karen E. Weck,
George A. Stouffer Tags: ORIGINAL RESEARCH Source Type: research
Janssen Submits New Drug Application to U.S. FDA for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, June 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of XARELTO® (rivaroxaban) in pediatric patients. The NDA seeks two pediatric indications: treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients aged birth to less than 18 years of age after at least five days of initial parenteral anticoagulant treatment; and thromboprophylaxis (prevention of blood clots) in patients aged 2 years and older with congenita...
Source: Johnson and Johnson - June 23, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Management of tandem occlusions in patients who receive rtPA
ConclusionThe use of GP2b3aI in the setting of tandem occlusions that required emergent stent placement post-rtPA appears safe and effective. Given the small sample size, these findings should be interpreted cautiously, and need to be confirmed in a larger patient population.
Source: Journal of Thrombosis and Thrombolysis - June 23, 2021 Category: Hematology Source Type: research
Outcomes of a multi-ethnic Asian population on combined treatment with clopidogrel and omeprazole in 12,440 patients
In conclusion, the use of clopidogrel with omeprazole is associated with an increased risk of MI, but not mortality or stroke, in this multi-ethnic Asian population. These risks appear to vary among different ethnic groups.
Source: Journal of Thrombosis and Thrombolysis - May 6, 2021 Category: Hematology Source Type: research
Platelet Function Monitoring Performed after Carotid Stenting during Endovascular Stroke Treatment Predicts Outcome
Antiplatelets agents are widely used and effective for secondary prevention of vascular diseases. Some patients might have reduced platelet inhibition on antiplatelet therapy with a higher risk of ischemic complications.1,2 The role of platelet function monitoring (PFM) has been extensively investigated in cardiology. Resistance to Clopidogrel correlates with higher risk of long-term cardiovascular events and coronary stent thrombosis.3,4 Similarly, studies performed after elective carotid stenting showed that ischemic recurrence and early stent thrombosis are more common in non-responders to Clopidogrel.
Source: Journal of Stroke and Cerebrovascular Diseases - May 5, 2021 Category: Neurology Authors: Ludovico Ciolli, Nicoletta Lelli, Francesca Rosafio, Stefania Maffei, Federico Sacchetti, Laura Vandelli, Maria Luisa Dell'Acqua, Livio Picchetto, Giuseppe Maria Borz ì, Riccardo Ricceri, Roberta Pentore, Manuela Tondelli, Gabriele Vandelli, Noelia Rodr Source Type: research
Long-term Outcomes of Clopidogrel Monotherapy versus Prolonged Dual Antiplatelet Therapy beyond 12 Months after Percutaneous Coronary Intervention in High-risk Patients
CONCLUSION: Compared with prolonged DAPT, clopidogrel monotherapy showed similar long-term outcomes in patients at high-risk after second-generation DES implantation.PMID:33904262 | DOI:10.3346/jkms.2021.36.e106
Source: J Korean Med Sci - April 27, 2021 Category: General Medicine Authors: Dong Yeon Kim Sung Woo Cho Kyu Tae Park Jong Hwa Ahn Taek Kyu Park Yong Ho Jang Ki Hong Choi Joo Myung Lee Jeong Hoon Yang Young Bin Song Jin Ho Choi Seung Hyuk Choi Hyeon Cheol Gwon Sang Hoon Lee Joo Yong Hahn Source Type: research
